Longevity & Cellular Health; Cognitive & Neuroprotection

NAD+ Boosting / Precursor Peptides

Last updated 12 August 2026

Evidence on file6 randomised human trials · 1 citation not yet graded

Strongest sourceChronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and… (randomised human trial)

Dosing on file unverified

IV: 250-1,000 mg per session; Oral NMN/NR: 250-1,000 mg/day; SubQ: 50-200 mg; IV: 250-1,000 mg; Oral NR/NMN: 300-1,000 mg/day; Intranasal: 25-50 mg

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Literature on file 7

human RCT
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”
human RCT
Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”
human RCT
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”
human RCT
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. graded on: a randomised trial — “randomized placebo-controlled clinical trial”
human RCT
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. graded on: randomised and placebo-controlled — “randomized, multicenter, double-blind, placebo-controlled”
human RCT
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. graded on: randomised and placebo-controlled — “Randomized, Double-Blind, Placebo-controlled”

Not graded

1 citation whose study design could not be read from the title. Left ungraded rather than guessed at.

not graded
Nicotinamide Riboside Kinase Structures Reveal New Pathways to NAD+ (2007, cited 139x)

Identity

Space-filling 3D model of NAD+ Boosting / Precursor Peptides, carbon grey, nitrogen blue, oxygen red — Built from the SMILES on this record — the atoms, bonds and stereochemistry are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

2D chemical structure of NAD+ Boosting / Precursor Peptides — Built from the SMILES on this record — the atoms, bonds and stereochemistry are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

Molecular weight: 664.4
Molecular formula: C21H28N7O14P2+
CAS number: 151411-04-0
PubChem CID: 5893 (NAD+)
InChI key: BAWFJGJZGIEFAR-NNYOXOHSSA-O
SMILES: C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N
InChI: InChI=1S/C21H27N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1-4,7-8,10-11,13-16,20-21,29-32H,5-6H2,(H5-,22,23,24,25,33,34,35,36,37)/p+1/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1

Also called

NAD+ Boosting Peptides
NAD+ Precursor Peptides

Caveat on these identifiers

Source files disagreed on evidence tier for this peptide.

Notes unverified prose

Clinical trials: ; oral NMN/NR safely raise NAD+ at 250-2,000 mg/day; NR 100-1,000 mg oral dose-dependent NAD+ increase; NMN 250-500 mg daily; NR 500 mg BID in trials; NR/NMN 250-1,000 mg/day; multiple human trials

Not on file 1

1 of the 8 fields we track hold nothing on this record, and each says why. A blank field is a bug; a named absence is a finding.

amino-acid sequencenot applicable to this compound

Each field links to every other record missing the same thing. The full ledger holds 521 gaps across 136 records.